Zobrazeno 1 - 10
of 119
pro vyhledávání: '"WOO-JONG LEE"'
Autor:
Eunsol Yang, Hyejung Choi, Jin‐Sol Park, Young‐Woock Noh, Chi‐Min Choi, Woo‐Jong Lee, Jae‐Wook Ko, Jungryul Kim
Publikováno v:
Clinical and Translational Science, Vol 14, Iss 6, Pp 2161-2170 (2021)
Abstract KMRC011 is a novel Toll‐like receptor 5 agonist under development as a treatment for acute radiation syndrome (ARS). The aim of this first‐in‐human study was to investigate the tolerability, pharmacokinetics, and pharmacodynamics of a
Externí odkaz:
https://doaj.org/article/62bbe7029529432185a4241bc6972dba
Autor:
Hong-Soo Lee, Doo-Wan Cho, Ji-Seok Han, Su-Cheol Han, Sang Keun Woo, Soo-Youn Jun, Woo-Jong Lee, Susie Yoon, Son-Il Pak, Sang-Jin Lee, Eunsol Seong, Eun-Jung Park
Publikováno v:
Journal of Immunotoxicology, Vol 17, Iss 1, Pp 31-42 (2020)
In the study here, the potential applicability of KMRC011 - an agonist of toll-like receptor-5 – as a countermeasure for radiation toxicities was evaluated. Following a single 5.5 Gy total body irradiation (TBI, surface absorbed dose = 7 Gy) of Co6
Externí odkaz:
https://doaj.org/article/ab49c49d45f04616ba9084cd90571b27
Autor:
Jeong Ho Lim, Mirza Masroor Ali Beg, Khurshid Ahmad, Sibhghatulla Shaikh, Syed Sayeed Ahmad, Hee Jin Chun, Dukhwan Choi, Woo-Jong Lee, Jun-O Jin, Jihoe Kim, Arif Tasleem Jan, Eun Ju Lee, Inho Choi
Publikováno v:
Cells, Vol 10, Iss 2, p 417 (2021)
IgLON5 is a cell adhesion protein belonging to the immunoglobulin superfamily and has important cellular functions. The objective of this study was to determine the role played by IgLON5 during myogenesis. We found IgLON5 expression progressively inc
Externí odkaz:
https://doaj.org/article/384bb5f77b0c4f858b59b10520044943
Publikováno v:
Korean Accounting Journal. 31:33-49
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7491fc9da46a974ab646e191e390b8e2
https://doi.org/10.24056/kaj.2022.08.003
https://doi.org/10.24056/kaj.2022.08.003
Publikováno v:
Journal of Microbiology and Biotechnology. 33:35-42
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e5a42d033ba772067e9ca264bb443aec
https://doi.org/10.4014/jmb.2209.09048
https://doi.org/10.4014/jmb.2209.09048
Publikováno v:
Korean Accounting Review. 47:77-105
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6a17bf2ff4518f29db4d9fcd30f22282
https://doi.org/10.24056/kar.2022.10.003
https://doi.org/10.24056/kar.2022.10.003
Publikováno v:
International Journal of Auditing.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f65048526552145be3961bedad64830a
https://doi.org/10.1111/ijau.12313
https://doi.org/10.1111/ijau.12313
Publikováno v:
Seoul Journal of Business; Dec2023, Vol. 29 Issue 2, p1-29, 29p
Publikováno v:
Korean Accounting Journal. 30:43-80
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a25e691a54761ddbf7499ac20d3c9460
https://doi.org/10.24056/kaj.2021.03.007
https://doi.org/10.24056/kaj.2021.03.007
Autor:
Young-Woock Noh, Chi-Min Choi, Woo-Jong Lee, Jung-Ryul Kim, Jae-Wook Ko, H.J. Choi, Eunsol Yang, Jin-Sol Park
Publikováno v:
Clinical and Translational Science
Clinical and Translational Science, Vol 14, Iss 6, Pp 2161-2170 (2021)
Clinical and Translational Science, Vol 14, Iss 6, Pp 2161-2170 (2021)
KMRC011 is a novel Toll‐like receptor 5 agonist under development as a treatment for acute radiation syndrome (ARS). The aim of this first‐in‐human study was to investigate the tolerability, pharmacokinetics, and pharmacodynamics of a single in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ea642477f70943188fade76f9bb47e6a
https://doi.org/10.1111/cts.13073
https://doi.org/10.1111/cts.13073